Keyphrases
Adhesive Layer
6%
Adverse Effects
33%
Allergic Contact Dermatitis
6%
Binding Site
6%
Bioavailability Study
6%
Blood Levels
6%
Cinnarizine
13%
Clinical Efficacy
6%
Clinical Pharmacology
100%
Clinical Treatment
100%
CNS Effects
6%
Cycloplegia
6%
Dimenhydrinate
13%
Drowsiness
20%
Dry Mouth
6%
Duration of Action
6%
Elderly Patients
6%
Ephedrine
13%
Erythema
6%
Fast Protection
6%
Functional Equivalent
6%
Headache
6%
Intra-individual
6%
Intravenous Infusion
6%
Long Journey
6%
Meclizine
13%
Memory Storage
6%
Motion Sickness
100%
Mydriasis
6%
Ocular Accommodation
6%
Oral Formulation
6%
Oral Therapy
6%
Parenteral Formulation
6%
Pediatric Patients
6%
Pharmacokinetic Application
100%
Place in Therapy
6%
Placebo
6%
Plasma Concentration
20%
Plaster
6%
Postauricular
6%
Priming Dose
6%
Promethazine
6%
Protective Concentrations
6%
Pyridostigmine
6%
Rash
6%
Recommended Dose
6%
Repeated Application
6%
Repeated Dose
6%
Scopolamine
100%
Seasickness
6%
Short-term Use
6%
Steady State
13%
Therapeutic Use
100%
Toxic Psychosis
6%
Transdermal
6%
Transdermal Drugs
53%
Transdermal Scopolamine
100%
Treatment Failure
6%
Pharmacology, Toxicology and Pharmaceutical Science
Accommodation Paralysis
6%
Adhesive Agent
6%
Adverse Event
31%
Binding Site
6%
Bioavailability
6%
Cinnarizine
12%
Clinical Pharmacokinetics
100%
Dimenhydrinate
12%
Ephedrine
6%
Erythema
6%
Headache
6%
Meclozine
12%
Motion Sickness
100%
Mydriasis
6%
Placebo
6%
Psychosis
6%
Pyridostigmine
6%
Rash
6%
Scopolamine
100%
Skin Allergy
6%
Transdermal
100%
Transmer
6%
Xerostomia
6%